A recently-issued decision from the Court of Appeals for the Federal Circuit may have implications on a pending case before the U.S. Supreme Court. That case, WesternGeco LLC v. ION Geophysical...
This case, Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals Int’l Ltd., arrived to the appeals court through an unusual, but not uncommon, route: a 35 U.S.C. §271(e)(4)(A) infringement...
In a case of déjà vu, the Court of Appeals for the Federal Circuit handed down Knowles Electronics LLC v. Iancu, on April 6, 2018. This case bears striking resemblance to an earlier-issued case this...
On March 27, 2018, the Court of Appeals for the Federal Circuit ruled in In re Brandt, which is just another case in a long line of cases dealing with ranges and obviousness under 35 U.S.C. §103....
U.S. Patent No. 9,889,100 B2 issued on February 13, 2018, for “Cannabidiol for Treatment of Severe and Refractory Graft-Versus-Host Disease.” The inventor is Moshe Yeshurun, and the...
On March 23, 2018, the Court of Appeals for the Federal Circuit handed down DSS Techs. Mgmt., Inc. v. Apple Inc., reversing two IPR decisions in Apple’s favor on a DSS-owned patent which the PTAB...
On March 19, 2018, the Court of Appeals for Federal Circuit handed down Dell Inc. v. Acceleron, LLC (and an erratum) In this case, the panel, composed of Judges Moore, Reyna, and Taranto, ruled that...
On March 19, 2018, the Court of Appeals for the Federal Circuit rejected, in In re Power Integrations, Inc., a PTAB decision finding that claims were invalidated as anticipated as unreasonably...
On March 14, 2018, the Court of Appeals for the Federal Circuit ruled on Hologic, Inc. v. Smith & Nephew, Inc., which deals with many areas in patents, including foreign applications, priority...
U.S. Patent No. 9,895,342 B2 issued on February 20, 2018, for “Cannabinoids for Use in the Treatment of Neuropathic Pain.” It is assigned to GW Pharma Ltd., which is a fairly large pharmaceutical...